Strober, B., Tada, Y., Mrowietz, U., Lebwohl, M., Foley, P., Langley, R. G., Barker, J., Wang, M., Vanvoorden, V., Szilagyi, B., Ciaravino, V., & Paul, C. (2022). Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial. SKIN The Journal of Cutaneous Medicine, 6(6), s65.